203 related articles for article (PubMed ID: 25909288)
1. OGFOD1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer.
Kim JH; Lee SM; Lee JH; Chun S; Kang BH; Kwak S; Roe JS; Kim TW; Kim H; Kim WH; Cho EJ; Youn HD
Oncotarget; 2015 Aug; 6(23):19528-41. PubMed ID: 25909288
[TBL] [Abstract][Full Text] [Related]
2. OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation.
Singleton RS; Liu-Yi P; Formenti F; Ge W; Sekirnik R; Fischer R; Adam J; Pollard PJ; Wolf A; Thalhammer A; Loenarz C; Flashman E; Yamamoto A; Coleman ML; Kessler BM; Wappner P; Schofield CJ; Ratcliffe PJ; Cockman ME
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4031-6. PubMed ID: 24550447
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of FAM64A suppresses proliferation and migration of breast cancer cells.
Yao Z; Zheng X; Lu S; He Z; Miao Y; Huang H; Chu X; Cai C; Zou F
Breast Cancer; 2019 Nov; 26(6):835-845. PubMed ID: 31264076
[TBL] [Abstract][Full Text] [Related]
4. OGFOD1, a member of the 2-oxoglutarate and iron dependent dioxygenase family, functions in ischemic signaling.
Saito K; Adachi N; Koyama H; Matsushita M
FEBS Lett; 2010 Aug; 584(15):3340-7. PubMed ID: 20579638
[TBL] [Abstract][Full Text] [Related]
5. Tristetraprolin induces cell cycle arrest in breast tumor cells through targeting AP-1/c-Jun and NF-κB pathway.
Xu L; Ning H; Gu L; Wang Q; Lu W; Peng H; Cui W; Ying B; Ross CR; Wilson GM; Wei L; Wold WS; Liu J
Oncotarget; 2015 Dec; 6(39):41679-91. PubMed ID: 26497679
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells.
Wang Y; Jin T; Dai X; Xu J
Biosci Trends; 2016 Feb; 10(1):67-73. PubMed ID: 26902787
[TBL] [Abstract][Full Text] [Related]
7. The prolyl hydroxylase OGFOD1 promotes cancer cell proliferation by regulating the expression of cell cycle regulators.
Fujisaki T; Saito K; Kikuchi T; Kondo E
FEBS Lett; 2023 Apr; 597(8):1073-1085. PubMed ID: 36464654
[TBL] [Abstract][Full Text] [Related]
8. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215.
Kong X; Duan Y; Sang Y; Li Y; Zhang H; Liang Y; Liu Y; Zhang N; Yang Q
J Cell Physiol; 2019 Jun; 234(6):9105-9117. PubMed ID: 30362551
[TBL] [Abstract][Full Text] [Related]
9. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of ER60 protease inhibits cellular proliferation by inducing G1/S arrest in breast cancer cells in vitro.
Lwin ZM; Yip GW; Chew FT; Bay BH
Anat Rec (Hoboken); 2012 Mar; 295(3):410-6. PubMed ID: 22266712
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells.
Han J; Zhang F; Yu M; Zhao P; Ji W; Zhang H; Wu B; Wang Y; Niu R
Cancer Lett; 2012 Aug; 321(1):80-8. PubMed ID: 22381696
[TBL] [Abstract][Full Text] [Related]
12. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
14. OGFOD1 negatively regulated by miR-1224-5p promotes proliferation in human papillomavirus-infected laryngeal papillomas.
Yin D; Wang Q; Wang S; Zhu G; Tang Q; Liu J
Mol Genet Genomics; 2020 May; 295(3):675-684. PubMed ID: 32002629
[TBL] [Abstract][Full Text] [Related]
15. SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas.
Kumar D; Sakabe I; Patel S; Zhang Y; Ahmad I; Gehan EA; Whiteside TL; Kasid U
Gene; 2004 Mar; 328():187-96. PubMed ID: 15019998
[TBL] [Abstract][Full Text] [Related]
16. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
17. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
18. Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression.
Kastner S; Voss T; Keuerleber S; Glöckel C; Freissmuth M; Sommergruber W
Mol Cancer Res; 2012 Oct; 10(10):1343-58. PubMed ID: 22912338
[TBL] [Abstract][Full Text] [Related]
19. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12.
Kishimoto H; Wang Z; Bhat-Nakshatri P; Chang D; Clarke R; Nakshatri H
Carcinogenesis; 2005 Oct; 26(10):1706-15. PubMed ID: 15917309
[TBL] [Abstract][Full Text] [Related]
20. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
